A
Adrienne W. Scott
Researcher at Johns Hopkins University School of Medicine
Publications - 76
Citations - 1447
Adrienne W. Scott is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Visual acuity & Fluorescein angiography. The author has an hindex of 17, co-authored 65 publications receiving 1117 citations. Previous affiliations of Adrienne W. Scott include Johns Hopkins University & Iran University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Imaging the infant retina with a hand-held spectral-domain optical coherence tomography device.
TL;DR: The hand-held customized SD OCT proved to be an invaluable tool in the differentiation of disease processes or injury in these eyes under study and may be considered a useful adjunct to RetCam fundus photography for assessment and clinical management in cases of SBS.
Journal ArticleDOI
Public Attitudes About Eye and Vision Health
TL;DR: In this well-characterized survey across all US ethnic and racial groups, vision health was a priority with high support for ongoing research for vision and eye health.
Journal ArticleDOI
Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
Peter A. Campochiaro,Gulnar Hafiz,Tahreem A. Mir,Adrienne W. Scott,Sharon D. Solomon,Ingrid Zimmer-Galler,Akrit Sodhi,Elia J. Duh,Howard S. Ying,Adam S. Wenick,Syed Mahmood Shah,Diana V. Do,Quan Dong Nguyen,Saleema Kherani,Raafay Sophie +14 more
TL;DR: In patients with macular edema resulting from RVO, there was no short-term clinically significant benefit from monthly injections of 2.0-mg versus 0.5-mg ranibizumab injections and no long-term benefit in BCVA, resolution of edema, or number of injections obtained by addition of laser treatment to ranibzumab.
Journal ArticleDOI
Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.
Raafay Sophie,Gulnar Hafiz,Adrienne W. Scott,Ingrid Zimmer-Galler,Quan Dong Nguyen,Howard S. Ying,Diana V. Do,Sharon D. Solomon,Akrit Sodhi,Peter L. Gehlbach,Elia J. Duh,David Baranano,Peter A. Campochiaro +12 more
TL;DR: In patients with RVO, infrequent ranibizumab injections to control edema may not be sufficient to prevent progression of retinal nonperfusion, which may contribute to loss of visual gains.
Journal ArticleDOI
Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
TL;DR: Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-veGF treatment shows these vision gains can be maintained through 2 years.